Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Physical Withdrawal Potential of Difelikefalin in Hemodialysis
NCT05533008Phase 1Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in uremic pruritus comparing CR845 Maintenance with Placebo Withdrawal (2 arms). Primary endpoint: Clinical Opiate Withdrawal Scale. Started Dec 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT05533008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533008.